# Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders

> **NCT01248130** · PHASE2 · TERMINATED · sponsor: **Massachusetts General Hospital** · enrollment: 7 (actual)

## Conditions studied

- Autism Spectrum Disorder (ASD)

## Interventions

- **DRUG:** Omega-3 Fatty Acid

## Key facts

- **NCT ID:** NCT01248130
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-11
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Due to a change in the research priorities of the principal investigator in combination with low subject interest.
- **Last updated:** 2025-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01248130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01248130, "Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01248130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*